HLC-001 is under clinical development by Human Life CORD Japan and currently in Phase II for Unspecified Respiratory Disorders. According to GlobalData, Phase II drugs for Unspecified Respiratory Disorders does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the HLC-001 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HLC-001 overview
HLC-001 is under development for the treatment of coronavirus disease 2019 (COVID-19) associated acute respiratory distress syndrome and non-infectious pulmonary complications (NIPCs) (idiopathic pneumonia syndrome). It is administered through intravenous route. The therapeutic candidate comprises of umbilical cord-derived mesenchymal stem cells.
For a complete picture of HLC-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
